.svg)
Latest Business News
The Next Big Thing in Weight Loss: The Rise of Oral Obesity Pills
Drugmakers are competing to tap into the booming weight loss industry by developing effective and convenient oral obesity pills. With 40% of American adults classified as obese, the potential market for these pills is enormous. While data from pivotal trials and pricing information is yet to be released, one experimental oral drug from Eli Lilly appears to have an advantage over its competitors, Novo Nordisk and Pfizer. All three companies are developing oral versions of GLP-1s, a hormone-mimicking drug that suppresses appetite.
Eli Lilly's Edge
Eli Lilly's experimental oral obesity pill, orforglipron, seems to have an edge over the pills being developed by Novo Nordisk and Pfizer. Although it may not be the first to receive U.S. approval, Eli Lilly has showcased strong efficacy results in its phase two clinical trials. Overweight or obese patients who took 45 milligrams of orforglipron once a day lost up to 14.7% of their body weight after 36 weeks, compared to a 2.3% weight loss for those who received a placebo. Analysts believe that orforglipron could potentially achieve even greater weight loss over a longer trial period.
Novo Nordisk's Semaglutide
Novo Nordisk's weight loss pill, semaglutide, has gained significant attention in the weight loss industry. Overweight or obese patients who took 50 milligrams of the drug once a day saw an average weight loss of 15.1% after 68 weeks. While Eli Lilly's orforglipron shows similar weight reduction, it achieved this result in a shorter trial period. Analysts believe that with an extended trial period, orforglipron could surpass the weight loss achieved by semaglutide.
Pfizer's Challenge
Pfizer's oral GLP-1, danuglipron, is still undergoing phase two clinical trials. In one trial, patients with Type 2 diabetes who took a 120-milligram version of danuglipron twice a day lost around 10 pounds on average after 16 weeks. However, it's challenging to compare danuglipron's efficacy to other oral GLP-1s due to differing patient populations and the lack of longer-term data. Eli Lilly's strong orforglipron data presents a challenge for Pfizer's product, especially considering the physician preference for once-daily pills.
Dietary Restrictions and Convenience
Novo Nordisk's semaglutide requires patients to take the pill on an empty stomach in the morning with limited water and a 30-minute waiting period before eating or taking other oral medications. This is because semaglutide is a peptide medication that is harder for the gut to absorb. On the other hand, oral GLP-1s from Eli Lilly and Pfizer are non-peptide drugs that are absorbed more easily and do not require dietary restrictions. Market research suggests that these restrictions associated with sem
The rise of oral obesity pills in the weight loss industry presents a lucrative opportunity for new businesses looking to capitalize on this growing market. Eli Lilly's experimental oral pill, orforglipron, has emerged as a strong contender with impressive efficacy results, showcasing its potential to address the obesity epidemic. Novo Nordisk's semaglutide and Pfizer's danuglipron are also in the race, but face challenges in terms of trial results and convenience.
For new businesses entering this space, partnering with Eli Lilly or exploring collaborations to leverage orforglipron's potential could be a strategic move. The strong efficacy data from its phase two clinical trials makes it an attractive option. By offering an effective and once-daily pill, it could be a preferred choice for both physicians and patients.
However, it is essential to consider factors beyond efficacy alone. Novo Nordisk's semaglutide, despite its dietary restrictions, has shown impressive weight loss results over a longer trial period. This indicates the importance of considering patient preferences and needs when developing obesity pills. By prioritizing convenience and ease of use, businesses could tap into a segment of the market that values simplicity and practicality.
The development of oral obesity pills is an exciting prospect for new businesses. By carefully assessing the advantages and disadvantages of each drug, considering market research on patient preferences, and leveraging partnerships with pharmaceutical companies, entrepreneurs can position themselves at the forefront of the weight loss industry's next big thing.
